Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @TalarisTx
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @TalarisTx
-
A few weeks ago, Shelly Wheaton's hair stylist gave her a unique present: a new
#kidney. “There are not words to tell somebody how much you appreciate the fact they gave you a second chance at life," Wheaton said following the surgery. Read their story:https://bit.ly/2s6UMuwHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Louisville resident and father Rob Waddell participated in Talaris' Phase 2 clinical trial ten years ago. Although he was born with genetic
#kidneydisease, Rob now lives free from immunosuppression with his new kidney. Listen to his story: https://bit.ly/2tyyClb#DonateLifepic.twitter.com/yzq2B97ps9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Meet Alvin Roth, the economist who won a Nobel Prize for his work to design "
#kidney exchanges" — which have revolutionized#kidneytransplants from thousands of people:https://www.bbc.com/news/business-50632630 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congratulations to Talaris CEO Scott Requadt who was just named to the
@BFLouisville 20 People to Know in Healthcare list. In his interview, he offers a perspective on the future of healthcare as an 18-year industry veteran: https://bit.ly/2GdjTPA pic.twitter.com/BIVpVflyCF
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Next month's
@BFLouisville Healthcare Heroes event will feature a Q&A with Talaris CEO Scott Requadt on healthcare innovation in Louisville and beyond. We're proud to be a part of the Louisville science and business communities. Read more:https://bit.ly/300UDp6Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A huge problem of immunosuppressive medications can be lack of access, which patients on Medicare are facing right now. This piece from transplant surgeon Matthew Cooper explaining the problem is worth a read for anyone interested in
#kidneydisease:https://bit.ly/36OPZx1Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We’re honored to be named a life science startup to watch in 2020 by
@biospace! It’s a big year for us as we expand our Ph3 trial to enroll patients undergoing#livingdonor#kidneytransplants at sites across the country. https://bit.ly/307JVwI pic.twitter.com/q99YfedJ0i
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Are you considering becoming a
#livingdonor for someone suffering from kidney disease?@UNOSNews offers brochures about directed and non-directed donation. Learn more about your options to make a difference: https://unos.org/transplant/living-donation/ …#DonateLifeHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Kidneytransplants save lives. But immunosuppressive medicine can introduce health risks to transplant recipients, including diabetes and decline of kidney function. Learn more about Talaris' therapeutic approach to free patients from these risks: https://bit.ly/2R7irDJ pic.twitter.com/Gl8MTv0orc
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Are you seeking a living donor
#kidneytransplant in the#Chicago or#Durham, NC area? You may be eligible for our clinical trial that has the potential to eliminate your need for immunosuppression. Learn more: https://www.clinicaltrials.gov/ct2/show/NCT03995901?spons=talaris&rank=1 …#kidneydisease#livingdonationpic.twitter.com/Vw07f6LLpZ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Welcome to 2020! This year,
#TeamTalaris is excited to expand our Phase 3 trial to sites across the U.S. for living donor#kidneytransplants. What are your 2020#resolutions?Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
2019 was an incredible year, filled with trial advancements, promising data and inspirational patient stories. We look forward to an even more productive 2020. Happy New Year!pic.twitter.com/n5gH0Eit55
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#TeamTalaris wishes you and your loved ones a happy holiday season. To celebrate the holidays, Talaris Therapeutics is making a donation to the@nkf Gift of Life Program.pic.twitter.com/GxfqwJDPCi
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Talaris’ Phase 3 trial for living donor
#kidneytransplant recipients has now launched at@DukeHealth in#Durham, NC! Learn more about our FREEDOM-1 trial that has the potential to help kidney transplant patients live free from chronic immunosuppression: https://www.clinicaltrials.gov/ct2/show/NCT03995901?spons=talaris&rank=1 …pic.twitter.com/HawEWpvUwj
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A pioneering
#kidneytransplant between a father and daughter will be celebrated in a new display at the Science Museum in London. Read more about the inspiring story and scientific breakthrough:https://www.bbc.com/news/uk-northern-ireland-50397413 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Talaris recently launched a Phase 3 clinical study at
@NorthwesternMed in#Chicago. If you are undergoing a#kidneytransplant from a living donor, you may be eligible to participate. Learn more: https://www.clinicaltrials.gov/ct2/show/NCT03995901?spons=talaris&rank=1 …#ChicagoMedicine#KidneyHealthpic.twitter.com/bDNEYn7K9F
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This weekend, Talaris founder Dr. Suzanne Ildstad will be in Florida at
#ASH19 presenting data on the potential of our therapy to induce immune tolerance in both matched related and unrelated recipients of living donor kidney transplants. Learn more: https://bit.ly/2OYyFiz pic.twitter.com/LqOdJQZDAE
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Talaris' Eric Gornstein, Head of New Product Planning, presented at the New Product Planning Summit in Boston this week. We were proud to lead a lively discussion on strategic considerations for effectively launching a new indication for a marketed drug.pic.twitter.com/ZhvE04Qrp5
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Talaris wishes you and your family a happy and safe Thanksgiving. Our team is grateful to work alongside dedicated colleagues, advocates and patients who share our mission.pic.twitter.com/1WsVSodGiU
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#DYK: Talaris' cell therapy is based on decades of research led by founder Dr. Suzanne Ildstad, who first began work on cellular therapies at@PittTweet in 1988. Take a deeper dive into our history:https://talaristx.com/about/company-history/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.